RAD 101
Alternative Names: 18F-RAD101; F18; RAD-101Latest Information Update: 18 Sep 2026
At a glance
- Originator Radiopharm Theranostics
- Developer Imperial College of Science, Technology and Medicine; Radiopharm Theranostics
- Class Diagnostic agents; Fluorine radioisotopes; Radiopharmaceutical diagnostics; Small molecules; Volatile fatty acids
- Mechanism of Action Radionuclide imaging enhancers
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Brain metastases; Glioma; Kidney disorders; Solid tumours
Most Recent Events
- 14 Sep 2026 Efficacy data from a phase IIb trial in Brain metastases released by Radiopharm Theranostics
- 17 Aug 2026 Radiopharm Theranostics schedules an End-of-Phase 2 (EOP2) meeting with the US FDA for design of a pivotal phase III trial in Brain metastases (Diagnosis) in USA (IV) in October 2026
- 17 Aug 2026 Radiopharm Theranostics plans a phase III trial in Brain metastases (Diagnosis) in USA (IV) by year end 2026